# Olmutinib

Source: https://onco.cc/drugs/olmutinib/  
OnCo record `olmutinib` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Olmutinib was a Korean-developed EGFR pill approved in South Korea in 2016 for lung cancers that had developed the T790M resistance mutation, the same niche as osimertinib; severe skin reactions and osimertinib's success ended its development.

## Summary

Hanmi Pharmaceutical's olmutinib became the first third-generation EGFR inhibitor to reach any market when South Korea's Ministry of Food and Drug Safety approved it in May 2016 for T790M-positive non-small cell lung cancer after first-line EGFR therapy. Boehringer Ingelheim licensed it worldwide but returned the rights within months after reports of fatal toxic epidermal necrolysis and Stevens-Johnson syndrome and after osimertinib's phase 3 results. Hanmi ended development in 2018 and the drug is no longer marketed. It is remembered as a case study in how a first-to-market approval on early data can be overtaken.

## Fields

- Kind: Treatment
- Status: withdrawn
- Last checked: 2026-09-08
- Also known as: HM61713; BI 1482694
- Tags: gap-fill; chembl-universe
- Brand: Olita
- Modality: Oral third-generation EGFR kinase inhibitor
- Mechanism: A covalent inhibitor that binds cysteine 797 of EGFR and blocks the T790M resistance mutation while sparing the normal receptor.

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Olmutinib
- Wikipedia: https://en.wikipedia.org/wiki/Olmutinib
- ChEMBL CHEMBL3545110: https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL3545110

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- technologies: [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)
- targets: [EGFR](https://onco.cc/targets/egfr/)
- drugs: [Osimertinib](https://onco.cc/drugs/osimertinib/)

---
JSON: https://onco.cc/api/v1/entities/olmutinib.json